Design, synthesis and biological evaluation of novel diosgenin-benzoic acid mustard hybrids with potential anti-proliferative activities in human hepatoma HepG2 cells.

To discover new lead compounds with anti-tumour activities, in the present study, natural diosgenin was hybridised with the reported benzoic acid mustard pharmacophore. The cytotoxicity of the resulting newly synthesised hybrids (-, -, and -) was then evaluated in three tumour cells (HepG2, MCF-7, and HeLa) as well as normal GES-1 cells. Among them, possessed the most potential anti-proliferative activity against HepG2 cells, with an IC value of 2.26 µM, which was 14.4-fold higher than that of diosgenin (IC = 32.63 µM). Furthermore, it showed weak cytotoxicity against GES-1 cells (IC > 100 µM), thus exhibiting good antiproliferative selectivity between normal and tumour cells. Moreover, could induce G0/G1 arrest and apoptosis of HepG2 cells. From a mechanistic perspective, regulated cell cycle-related proteins (CDK2, CDK4, CDK6, cyclin D1 and cyclin E1) as well mitochondrial apoptosis pathway-related proteins (Bax, Bcl-2, caspase 9, and caspase 3). These findings suggested that hybrid serves as a promising anti-hepatoma lead compound that deserves further research.